Conditions: ALS
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 15
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the safety of oral edaravone at a dose of 105 mg administered once daily for 10 days out of a 14-day period, followed by a 14-day drug-free period. This study will be continued until the earlier date when oral edaravone is commercially available at each site in Japan or August 2023.

Detailed description:

Arms:
arm 1: Subjects receive the edaravone oral suspension orally once daily for 10 days out of a 14-day period, followed by a 14-day drug-free period.

Interventions: intervention 1: MT-1186
Intervention descriptions: intervention 1: Suspension

Protocol document:
Prot_000.pdf: 











































































































































SAP_001.pdf: